Logo for Theravance Biopharma Inc

Theravance Biopharma Investor Relations Material

Latest events

Logo for Theravance Biopharma Inc

Q3 2024

Theravance Biopharma
Logo for Theravance Biopharma

Q3 2024

12 Nov, 2024
Logo for Theravance Biopharma

Q2 2024

5 Aug, 2024
Access the full event backlog
Slides, Transcripts, and Reports from 11,000+ public companies

Latest reports from Theravance Biopharma Inc

Access all reports
Theravance Biopharma Inc. is a biopharmaceutical company that focuses on the discovery, development, and commercialization of respiratory and organ-selective medicines. The company's primary product is YUPELRI (revefenacin), a once-daily nebulized therapy used for the maintenance treatment of chronic obstructive pulmonary disease (COPD). Theravance Biopharma is also involved in the development of Ampreloxetine, an investigational norepinephrine reuptake inhibitor, targeting neurogenic orthostatic hypotension, and has collaborations for additional research in respiratory and immunological disorders. The company is headquartered in South San Francisco, California, and its shares are listed on the NASDAQ.